We measured concentrations of guanosine 3',5'-monophosphate (cGMP) in plasma and urine of healthy subjects and patients with congestive heart failure, renal impairment, neoplastic disease, and hepatic cirrhosis.There was no correlation between cGMP concentrationsin urine and in plasma. In all patients except those with renal impairment, urinary cGMP concentrations were significantly higher than in healthy persons. Only patients with heart failure or renal impairment showed significantlyincreased plasma CGMP concentrations. In contrast, CGMP in urine does not relate to the clinicallyassessed severity of heart failure (New York Heart Association functional classes). Determination of cGMP in plasma results in higher sensitivity and specificityfor diagnosing heart failure than measurement of CGMP in urine. for the diagnosis of heart failure.
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IndexIngTerms: liver disease/kidney disease/cancer/atrial natiluretic peptide
Heart failure is not simply a hemodynamic disorder, and its physiologic abnormalities cannot be assessed only by measurement of pressure, volume, and flow. It is also the interplay of neurohormonal and hemodynamic forces (1) . Any for the diagnosis of heart failure.
Subjects and Methods

Methods
Specimen collection. The underlying causes were ischemic heart disease (n = 25), valvular heart disease (n = 9), cardiomyopathy (n = 12), and congestive heart failure of unknown origin (n = 4). At blood withdrawal, edema was present in 32%, pulmonary congestion in 39%, tachycardia in 16%, orthopnea in 16%, dyspnea in 42%, and cardiac hypertrophy in 13%. In 32 patients, LVEF was measured by radionicide ventriculography. LVEF of patients ranged from 15% to 66% (33% ± 13%). Plasma creatinine concentrations were 90 ± 27 mol/L (range 35-150 pmol/L). volunteers.
Patients were
The distribution of urinary cGMP values in these patients is shown in Fig. 1 . There was no relation between cGMP concentrations in urine and the severity of heart failure according to NYHA functional classes (Fig. 2A) . In plasma, by contrast, there was a clear correlation between cGMP concentrations and the severity of heart failure (Fig. 2B) . cGMP plasma concentrations in patients with congestive heart failure were
NThAU
NYIfAW NYHAIV (n=13) (r21) (n-IS) Grouping of patients according to either etiologr of heart failure or clinical symptoms revealed no significant influence of these variables on plasma or urinary cGMP concentrations. Plasma and urinary cGMP concentrations were significantly lower in patients who received ACE inhibitors (P = 0.018 and P = 0.025, respectively; n = 4) and significantly higher in patients who received diuretics (P = 0.047 and P = 0.042, respectively; n = 22).
FIg. 2. Distributionof urinary(A) and plasma ( CGMP concentrations in patients with
For determination
of diagnostic sensitivity and specificity of urinary cGMP excretion in cardiovascular disease, we quantified cGMP in urine in 50 patients with congestive heart failure and in 143 patients with noncardiac diseases.
The upper cutoff value for urinary cGMP that gave the maximal Youden index (15) for diagnosis of heart failure was 0.5 mol/g creatinine (Fig. 3) . This cutoff value provided efficiency of 0.705 with diagnostic specificity of 64% and sensitivity of 88% (Table 1) .
Patients with renal impairment. In these patients (n = 29), cGMP concentrations in urine were significantly lower (P = 0.017) than they were in healthy volunteers In two patients with CLL, three patients with nonHodgkin lymphoma, three patients with multiple myeloma, nine patients with neoplasm of the lung, and four patients with gastrointestinal tumors, we simultaneously measured cGMP concentrations in urine (0.908 ± 0.561 pmol/g creatinine, range 0.061-2.428 pmoI/g). Of the 21 investigated patients (Fig. 1), 11 (1 This divergence between urine and plasma cGMP concentrations remains to be investigated; however, it reduces the specificity of cGMP concentration in urine for diagnosis of heart failure.
cGMP measurement in urine provides a sensitivity of 88% and a specificity of 64.3% for diagnosing heart failure, which was lower than the corresponding values (sensitivity 94%, specificity 94%) obtained with determination in plasma samples (9). In heart failure, right atrial pressure is reported to correlate positively with urinary cGMP concentrations and excretion rate (6). In contrast to plasma cGMP, in our patients urinary cGMP was not related to the severity of heart failure assessed clinically according to the NYHA. Plasma cGMP concentrations did not differ significantly between stage III and stage N patients. In severe heart failure there is an uncoupling of plasma ANP concentrations and cGMP production in the pulmonary and peripheral circulation, probably caused by receptor down-regulation (4, 8). In patients treated with diifent therapeutic agents, plasma and urinary cGMP concentrations differed significantly. Because of the relatively small number studied and the overlap between treatment and severity of congestive heart failure, it is not possible to attribute these observations to the effect of different drugs. However, the use of medications that may affect plasma ANP or CGMP concentrations (ACE inhibitors and diuretics, respectively) may have affected the outcome of this study and thus limited the applicability of these results to pretreated heart failure patients.
In summary, measurement of cGMP in plasma is superior to measurement of this cyclic nucleotide in urine for diagnosing and monitoring heart failure. However, simultaneous determination of cGMP in a patient's urine and plasma allows one to identify the causes of an increase in plasma cGMP concentrations, i.e., impaired renal clearance or increased systemic production.
